All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Spero Therapeutics LLC completed a $51.7 million series C preferred financing led by new investor GV (formerly Google Ventures) with the participation of additional new investors RA Capital Management and Rock Springs Capital as well as existing investors, including Atlas Venture, S.R. One Ltd., MRL Ventures Fund, Lundbeckfonden Ventures, the Kraft Group and Osage University Partners.